Ian T. Bothwell was named Chief Executive Officer of Zeo ScientifiX, Inc. As of November 14, 2026, Zeo ScientifiX, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from January 5, 2026 to March 27, 2026, naming 1 appointment (Form 8-K, January 5, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Zeo ScientifiX, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-03-27
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-01-28
- · In / out: In · Person: Ian T. Bothwell · Role: Chief Executive Officer · 8-K, 2026-01-05
Zeo ScientifiX, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-01-05 to 2026-03-27. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Zeo ScientifiX, Inc. files it.
Also on the record for Zeo ScientifiX, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 24, 2026 | Stake report, Schedule 13D/A, by Greyt Ventures, LLC | 23.88% of the class | 5%+ stakes | Source |
| July 24, 2026 | Stake report, Schedule 13D/A, by IAN T BOTHWELL | 20.6% of the class | 5%+ stakes | Source |
| July 24, 2026 | Stake report, Schedule 13G/A, by Shapiro George Craig | 15.1% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13D/A, by IAN T BOTHWELL | 14.7% of the class | 5%+ stakes | Source |
| February 6, 2026 | Stake report, Schedule 13D/A, by Greyt Ventures, LLC | 17.52% of the class | 5%+ stakes | Source |
| December 5, 2025 | Form D, private offering | $500K sold | Form D page | Source |
| October 20, 2025 | Stake report, Schedule 13D/A, by Skycrest Holdings, LLC | 7.04% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Zeo ScientifiX, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Zeo ScientifiX, Inc. and the records around it.
Zeo ScientifiX, Inc. elsewhere on the record
- 5%+ stake filings Jul 2026
- Company profile and every filing Dec 2025
- Form D filing Dec 2025
- Who owns it
Watch Zeo ScientifiX, Inc.
Get an email when Zeo ScientifiX, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Zeo ScientifiX, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Zeo ScientifiX, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Zeo ScientifiX, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-27 | Reported | not named in the filing | 8-K, 2026-03-27 | ||
| 2026-01-28 | Reported | not named in the filing | 8-K, 2026-01-28 | ||
| 2026-01-05 | In | Chief Executive Officer | 8-K, 2026-01-05 |
Who leads Zeo ScientifiX, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Executive Officer: Ian T. Bothwell, appointed (filed 2026-01-05).
New leaders reset buying decisions — get the Full Report on Zeo ScientifiX, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at Zeo ScientifiX, Inc., with the record behind each one.
Find candidates like Chief Executive Officer at Zeo ScientifiX, Inc.Every change, in the filing's words
Reported
Effective March 23, 2026, the Company terminated the employment of Dr. John D. Kisiday, Ph.D. as its Chief Science Officer. 1
Reported
(" Dr. Kisiday" ) was appointed the Company's Chief Science Officer.
- Dr. Kisiday, 55, has almost 30 years of experience in the development and translation of tissue-engineering and regenerative-medicine therapies.
- His work includes therapies based on cells, biomaterials, and drugs intended for orthopedic applications.
- He has broad expertise in basic research, autologous cell-therapy development, multidisciplinary scientific collaboration, and the generation and critical evaluation of high-quality scientific data.
- From September 2022 until joining ZEO, Dr. Kisiday served as an independent scientific consultant, advising companies engaged in orthobiologics and biomaterials for delivery of drugs and/or cells.
- Concurrently, Dr. Kisiday served as an Adjunct Professor in the Department of Chemical Engineering at the University of Wyoming where he taught courses in biomaterials and biotransport, supervised research, and developed proposals for the use of microparticle scaffolds for cell and drug delivery.
- From 2005 to September 2022, Dr. Kisiday held faculty appointments in the Department of Clinical Sciences at Colorado State University, where he advanced from Assistant Professor to Associate Professor with tenure.
- His academic work focused on mesenchymal stromal cell and connective tissue cell expansion and differentiation, orthobiologics, cartilage tissue engineering, and mechanobiology.
Appointed: Ian T. Bothwell, Chief Executive Officer
Effective December 24. 2025, ZEO's board of directors appointed Ian T. Bothwell, who has been serving as ZEO's Interim Chief Executive Officer in addition to Chief Financial Officer, as the Company's full-time Chief Executive Officer.
Tools for this story
Each opens in a new tab, filled in for Zeo ScientifiX, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
